CO5170528A1 - ANTAGONISTS OF IL-8 RECEIVERS RECEIVERS OF IL-8 - Google Patents
ANTAGONISTS OF IL-8 RECEIVERS RECEIVERS OF IL-8Info
- Publication number
- CO5170528A1 CO5170528A1 CO00038191A CO00038191A CO5170528A1 CO 5170528 A1 CO5170528 A1 CO 5170528A1 CO 00038191 A CO00038191 A CO 00038191A CO 00038191 A CO00038191 A CO 00038191A CO 5170528 A1 CO5170528 A1 CO 5170528A1
- Authority
- CO
- Colombia
- Prior art keywords
- alkyl
- cr8r8
- alkenyl
- heteroaryl
- optionally substituted
- Prior art date
Links
- 108090001007 Interleukin-8 Proteins 0.000 title 2
- 239000005557 antagonist Substances 0.000 title 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 6
- 125000000217 alkyl group Chemical group 0.000 abstract 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 6
- 125000001072 heteroaryl group Chemical group 0.000 abstract 5
- 229910052757 nitrogen Inorganic materials 0.000 abstract 4
- 125000003342 alkenyl group Chemical group 0.000 abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 150000002431 hydrogen Chemical class 0.000 abstract 3
- 125000000027 (C1-C10) alkoxy group Chemical group 0.000 abstract 2
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 2
- 125000005842 heteroatom Chemical group 0.000 abstract 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 239000001301 oxygen Substances 0.000 abstract 2
- 125000003107 substituted aryl group Chemical group 0.000 abstract 2
- 229910052717 sulfur Inorganic materials 0.000 abstract 2
- 239000011593 sulfur Substances 0.000 abstract 2
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 abstract 1
- 125000005018 aryl alkenyl group Chemical group 0.000 abstract 1
- -1 aryl- C2-4 alkenyl Chemical group 0.000 abstract 1
- 125000004104 aryloxy group Chemical group 0.000 abstract 1
- 150000001540 azides Chemical class 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000004447 heteroarylalkenyl group Chemical group 0.000 abstract 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 125000004449 heterocyclylalkenyl group Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/18—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to carbon atoms of six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/44—Nitrogen atoms not forming part of a nitro radical
- C07D233/50—Nitrogen atoms not forming part of a nitro radical with carbocyclic radicals directly attached to said nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/88—Nitrogen atoms, e.g. allantoin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Un compuesto de la fórmula (I):<EMI FILE="00038191_1" ID="1" IMF=JPEG >donde:R es OH, SH, NHSO2Rd;Rd es NR6R7, alquilo, aril-alquilo C1-4, aril-alquenilo C2-4, heteroarilo, heteroaril-alquilo C1-4, heteroaril-alquenilo C2-4, radical heterocíclico, heterociclil-alquilo C1-4, donde los anillos arilo, heteoarilo y heterocíclico pueden estar opcionalmente sustituidos;R6 y R7 son, independientemente, hidrógeno, o un grupo alquilo C1-4, o R6 y R7, junto con el nitrógeno al que están unidos, forman un anillo de 5 a 7 miembros, cuyo anillo puede contener opcionalmente un heteroátomo adicional que se selecciona entre oxígeno, nitrógeno o azufre, y cuyo anillo puede estar opcionalmente sustituido;R1 se selecciona, independientemente, entre hidrógeno, halógeno, nitro, ciano, alquilo C1-10 halosustituido, alquilo C1-10, alquenilo C2-10, alcoxi C1-10, alcoxi C1-10 halosustituido, azida, (CR8R8)qS(O)tR4, hidroxi, hidroxi-alquilo C1-4, arilo, aril-alquilo C1-4, ariloxi, aril-alquiloxi C1-4, heteroarilo, heteroarilalquilo, radical heterocíclico, heterociclil-alquilo C1-4, heteroaril-alquiloxi C1-4, aril-alquenilo C2-10, heteroaril-alquenilo C2-10, heterociclil-alquenilo C2-10, (CR8R8)qNR4R5, alquenil C2-10-C(O)NR4R5, (CR8R8)qC(O)NR4R5, (CR8R8)qC(O)NR4R10, S(O)3H, S(O)3R8, (CR8R8)qC(O)R11, alquenil C2-10-C(O)R11, alquenil C2-10-C(O)OR11, (CR8R8)qC(O)OR12, (CR8R8)qOC(O)R11, (CR8R8)qNR4C(O)R11, (CR8R8)qNHS(O)2R17, (CR8R8)qS(O)2NR4R5, o dos restos R1 juntos pueden formar O-(CH2)sO- o un anillo insaturado de 5 a 6 miembros;q es 0, o un número entero que tiene un valor de 1 a 10; t es 0, o un número entero que tiene un valor de 1 ó 2;s es un número entero que tiene un valor de 1 a 3;R4 y R5 son, independientemente, hidrógeno, alquilo C1-4 opcionalmente sustituido, arilo opcionalmente sustituido, (aril opcionalmente sustituido)-alquilo C1-4, heteroarilo opcionalmente sustituido, (heteroaril opcionalmente sustituido)-alquilo C1-4, radical heterocíclico, heterociclil-alquilo C1-4, o R4 y R5, junto con el nitrógeno al que están unidos, forman un anillo de 5 a 7 miembros que puede contener opcionalmente un heteroátomo adicional seleccionado entre oxígeno, nitrógeno o azufre; ...A compound of the formula (I): <EMI FILE = "00038191_1" ID = "1" MFI = JPEG> where: R is OH, SH, NHSO2Rd; Rd is NR6R7, alkyl, aryl-C1-4 alkyl, aryl- C2-4 alkenyl, heteroaryl, heteroaryl-C1-4 alkyl, heteroaryl-C2-4 alkenyl, heterocyclic radical, heterocyclyl-C1-4 alkyl, where the aryl, heteroaryl and heterocyclic rings may be optionally substituted; R6 and R7 are independently , hydrogen, or a C1-4 alkyl group, or R6 and R7, together with the nitrogen to which they are attached, form a 5- to 7-membered ring, the ring of which may optionally contain an additional heteroatom that is selected from oxygen, nitrogen or sulfur, and whose ring may be optionally substituted; R1 is independently selected from hydrogen, halogen, nitro, cyano, halosubstituted C1-10 alkyl, C1-10 alkyl, C2-10 alkenyl, C1-10 alkoxy, C1-10 alkoxy halosubstituted, azide, (CR8R8) qS (O) tR4, hydroxy, hydroxyC 1-4 alkyl, aryl, arylC 1-4 alkyl, aryloxy, arylC 1-4 alkyloxy , heteroaryl, heteroarylalkyl, heterocyclic radical, heterocyclyl-C1-4 alkyl, heteroaryl-C1-4 alkyloxy, C2-10 aryl-alkenyl, C2-10 heteroaryl-alkenyl, C2-10 heterocyclyl-alkenyl, (CR8R8) qNR4R5, C2 alkenyl -10-C (O) NR4R5, (CR8R8) qC (O) NR4R5, (CR8R8) qC (O) NR4R10, S (O) 3H, S (O) 3R8, (CR8R8) qC (O) R11, C2 alkenyl -10-C (O) R11, alkenyl C2-10-C (O) OR11, (CR8R8) qC (O) OR12, (CR8R8) qOC (O) R11, (CR8R8) qNR4C (O) R11, (CR8R8) qNHS (O) 2R17, (CR8R8) qS (O) 2NR4R5, or two R1 moieties together can form O- (CH2) sO- or an unsaturated ring of 5 to 6 members; q is 0, or an integer that has a value from 1 to 10; t is 0, or an integer having a value of 1 or 2; s is an integer having a value of 1 to 3; R4 and R5 are, independently, hydrogen, optionally substituted C1-4 alkyl, optionally substituted aryl , (optionally substituted aryl) -C 1-4 alkyl, optionally substituted heteroaryl, (optionally substituted heteroaryl) -C 1-4 alkyl, heterocyclic radical, heterocyclyl-C 1-4 alkyl, or R 4 and R 5, together with the nitrogen to which they are attached , form a 5 to 7 member ring that may optionally contain an additional heteroatom selected from oxygen, nitrogen or sulfur; ...
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13666599P | 1999-05-28 | 1999-05-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5170528A1 true CO5170528A1 (en) | 2002-06-27 |
Family
ID=22473833
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO00038191A CO5170528A1 (en) | 1999-05-28 | 2000-05-24 | ANTAGONISTS OF IL-8 RECEIVERS RECEIVERS OF IL-8 |
Country Status (20)
| Country | Link |
|---|---|
| EP (1) | EP1180025A4 (en) |
| JP (1) | JP2003500443A (en) |
| KR (1) | KR20020016806A (en) |
| CN (1) | CN1352554A (en) |
| AR (1) | AR029361A1 (en) |
| AU (1) | AU766999B2 (en) |
| BR (1) | BR0010863A (en) |
| CA (1) | CA2374295A1 (en) |
| CO (1) | CO5170528A1 (en) |
| CZ (1) | CZ20014246A3 (en) |
| HK (1) | HK1045256A1 (en) |
| HU (1) | HUP0201302A3 (en) |
| IL (1) | IL146053A0 (en) |
| MX (1) | MXPA01012267A (en) |
| NO (1) | NO20015774D0 (en) |
| NZ (1) | NZ514728A (en) |
| PL (1) | PL351947A1 (en) |
| TR (1) | TR200103354T2 (en) |
| WO (1) | WO2000072840A1 (en) |
| ZA (1) | ZA200109627B (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU6230300A (en) * | 1999-07-21 | 2001-02-13 | Kadmus Pharmaceuticals, Inc. | Substituted guanidines and the use thereof |
| EP1413302A3 (en) * | 1999-07-21 | 2004-05-12 | Kadmus Pharmaceuticals, Inc. | Substituted guanidines for the treatment of pain |
| US6875759B1 (en) | 1999-07-21 | 2005-04-05 | Kadmus Pharmaceuticals | Substituted guanidines and the use thereof |
| US6949567B2 (en) | 2001-02-26 | 2005-09-27 | 4Sc Ag | Compounds for the treatment of protozoal diseases |
| DE10109204A1 (en) * | 2001-02-26 | 2002-09-19 | 4Sc Ag | Use of new and known diphenylurea compounds for the preparation of a medicament for the inhibition of intracellular protein-degradation pathway |
| JP2006525254A (en) | 2003-05-01 | 2006-11-09 | エフ．ホフマン−ラ ロシュ アーゲー | Imidazolin-2-ylamino-phenylamides as IP antagonists |
| CN101531621B (en) * | 2009-04-14 | 2012-08-15 | 厦门康奥克科技有限公司 | Method for preparing guanidine compound |
| AU2018354418A1 (en) * | 2017-10-27 | 2020-05-14 | Immunebridge Inc. | Compositions and methods of making expanded hematopoietic stem cells using derivatives of fluorene |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US605977A (en) * | 1898-06-21 | Bruno richard seifert | ||
| US1953494A (en) * | 1926-08-26 | 1934-04-03 | Ig Farbenindustrie Ag | Process of preparing substituted guanidines |
| US3914306A (en) * | 1972-09-22 | 1975-10-21 | Rorer Inc William H | Guanidines |
| US5696290A (en) * | 1994-09-12 | 1997-12-09 | Monsanto Company | Synthesis of penta-substituted guanidines |
| WO1996025157A1 (en) * | 1995-02-17 | 1996-08-22 | Smithkline Beecham Corporation | Il-8 receptor antagonists |
| AR008290A1 (en) * | 1996-08-15 | 1999-12-29 | Smithkline Beecham Corp | NEW COMPOUNDS CONTAINING GUANIDINE USEFUL AS ANTAGONISTS OF IL-8 RECEPTORS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM PROCEDURE FOR THE PREPARATION OF SUCH COMPOUNDS AND PROCEDURE FOR THE PREPARATION OF INTERMEDIARIES. |
| WO2000072800A2 (en) * | 1999-05-28 | 2000-12-07 | Smithkline Beecham Corporation | Il-8 receptor antagonists |
| UY26627A1 (en) * | 2000-03-24 | 2001-09-28 | Smithkline Beecham Corp | IL-8 RECEPTOR ANTAGONISTS |
-
2000
- 2000-05-24 AR ARP000102556A patent/AR029361A1/en unknown
- 2000-05-24 CO CO00038191A patent/CO5170528A1/en not_active Application Discontinuation
- 2000-05-26 HK HK02105335.1A patent/HK1045256A1/en unknown
- 2000-05-26 AU AU51690/00A patent/AU766999B2/en not_active Ceased
- 2000-05-26 CN CN00808133A patent/CN1352554A/en active Pending
- 2000-05-26 IL IL14605300A patent/IL146053A0/en unknown
- 2000-05-26 KR KR1020017015176A patent/KR20020016806A/en not_active Withdrawn
- 2000-05-26 HU HU0201302A patent/HUP0201302A3/en unknown
- 2000-05-26 CA CA002374295A patent/CA2374295A1/en not_active Abandoned
- 2000-05-26 TR TR2001/03354T patent/TR200103354T2/en unknown
- 2000-05-26 EP EP00936368A patent/EP1180025A4/en not_active Withdrawn
- 2000-05-26 CZ CZ20014246A patent/CZ20014246A3/en unknown
- 2000-05-26 MX MXPA01012267A patent/MXPA01012267A/en unknown
- 2000-05-26 JP JP2000620952A patent/JP2003500443A/en not_active Withdrawn
- 2000-05-26 BR BR0010863-4A patent/BR0010863A/en not_active IP Right Cessation
- 2000-05-26 WO PCT/US2000/014660 patent/WO2000072840A1/en not_active Application Discontinuation
- 2000-05-26 NZ NZ514728A patent/NZ514728A/en not_active Application Discontinuation
- 2000-05-26 PL PL00351947A patent/PL351947A1/en not_active Application Discontinuation
-
2001
- 2001-11-22 ZA ZA200109267A patent/ZA200109627B/en unknown
- 2001-11-27 NO NO20015774A patent/NO20015774D0/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| HUP0201302A2 (en) | 2002-12-28 |
| IL146053A0 (en) | 2002-07-25 |
| HUP0201302A3 (en) | 2003-02-28 |
| EP1180025A1 (en) | 2002-02-20 |
| NO20015774L (en) | 2001-11-27 |
| AU766999B2 (en) | 2003-10-30 |
| WO2000072840A1 (en) | 2000-12-07 |
| AR029361A1 (en) | 2003-06-25 |
| CA2374295A1 (en) | 2000-12-07 |
| BR0010863A (en) | 2002-02-19 |
| NZ514728A (en) | 2004-04-30 |
| HK1045256A1 (en) | 2002-11-22 |
| JP2003500443A (en) | 2003-01-07 |
| CZ20014246A3 (en) | 2002-05-15 |
| TR200103354T2 (en) | 2002-06-21 |
| AU5169000A (en) | 2000-12-18 |
| CN1352554A (en) | 2002-06-05 |
| ZA200109627B (en) | 2002-11-28 |
| MXPA01012267A (en) | 2002-07-30 |
| EP1180025A4 (en) | 2002-08-28 |
| PL351947A1 (en) | 2003-07-14 |
| NO20015774D0 (en) | 2001-11-27 |
| KR20020016806A (en) | 2002-03-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO5170514A1 (en) | ANTAGONISTS OF IL-8 RECEIVERS RECEIVERS OF IL-8 | |
| CO4970747A1 (en) | IL-8 RECEPTOR ANTAGONISTS | |
| CO5251467A1 (en) | PIPERAZINE DERIVATIVES | |
| CO4940442A1 (en) | DERIVATIVES OF 4-BROMINE OR 4-IODINE PHENYLAMINO ACID BENZHIDROXAMICO | |
| AR076896A2 (en) | A METHOD FOR INHIBITING PREMATURE POLYMERIZATION OF ETHENICALLY INSATURED MONOMERS | |
| AR032398A1 (en) | SULFONAMIDE ESCUARAMIDE COMPOUND, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND USE OF THIS COMPOUND TO PREPARE SUCH COMPOSITION | |
| CO5140087A1 (en) | DERIVATIVES OF 3-PHENYL-PYRIDINE YOUR SYNTHESIS PROCEDURE AND MEDICINES CONTAINING THEM | |
| ATE369855T1 (en) | MODULATORS OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS | |
| CO5170528A1 (en) | ANTAGONISTS OF IL-8 RECEIVERS RECEIVERS OF IL-8 | |
| CO5150159A1 (en) | DERIVATIVES OF 4-ARILQUINOLIN-2-ONA 3-SUBSTITUTED AS MODULATORS OF THE POTASSIUM CHANNELS | |
| HUP9903922A2 (en) | Il-8 receptor antagonists | |
| CO5601012A2 (en) | COMPOUNDS THAT MODULATE THE ACTIVITY OF PPAR | |
| ES8607970A1 (en) | A PROCEDURE FOR THE OBTAINING OF HEXAHYDRO-3-OXO-PIRIDINE DERIVATIVES. | |
| NO20004090D0 (en) | Chemical connections | |
| AR033803A1 (en) | DIANILINO ESCUARANO COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND THEM, AND THE USE OF THE SAME IN THE MANUFACTURE OF MEDICINES TO TREAT CHEMIOQUINE MEDIUM-RELATED DISEASES | |
| CO5031286A1 (en) | CIANO GUANADINA COMPOUNDS AS ANTAGONISTS OF IL-8 RECEPTORS AND PREPARATION METHOD | |
| CO5271716A1 (en) | CRYSTALS OF 4- CARBOXAMINE 1,2,3,4-TETRAHYDROQUINOLINE 2- REPLACED | |
| CO5200760A1 (en) | RECEIVER ANTAGONISTS OF IL-8 CEPTOR IL-8 | |
| AR008331A1 (en) | ANTAGONIST COMPOUNDS OF AN IL-8 RECEPTOR, USE OF THE SAME FOR THE MANUFACTURE OF MEDICINES, PROCEDURE FOR THEIR OBTAINING, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM | |
| ATE409180T1 (en) | SYNTHESIS OF CYCLOPENTADIENE DERIVATIVES | |
| CO5190696A1 (en) | ANTAGONISTS OF IL-8 RECEIVERS | |
| CO5170526A1 (en) | NEW USEFUL CYCLING GUANIDINE COMPOUNDS AS ANTAGONIS TAS OF THE IL-8 RECEIVER | |
| AR006189A1 (en) | AMINOALKYL-ETERS AND ACILAMINOALKYL-ETERES, PROCEDURE FOR THEIR PREPARATION AND USE AS BRADIQUININE RECEPTOR ANTAGONISTS | |
| AR015426A1 (en) | BENZOTIAZOL COMPOUNDS ANTAGONISTS OF THE IL-8 RECEPTOR, PHARMACEUTICAL COMPOSITION CONTAINING THEM, ITS USE FOR THE MANUFACTURE OF A MEDICINAL PRODUCT, PROCEDURE FOR PREPARATION, INTERMEDIARY COMPOUNDS AND PROCEDURE FOR PREPARATION | |
| CO5271664A1 (en) | ANTAGONISTS OF IL-8 RECEIVERS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Application refused |